

**FORM 3****UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**OMB APPROVAL**

OMB Number: 3235-0104  
 Estimated average burden  
 hours per response: 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934  
 or Section 30(h) of the Investment Company Act of 1940

<b>1. Name and Address of Reporting Person*</b> <u>Beer Marc D</u> <hr/> (Last) (First) (Middle) <u>C/O MINERVA NEUROSCIENCES, INC.</u> <u>245 FIRST STREET, SUITE 1800</u> <hr/> (Street) <u>CAMBRIDGE MA</u> <u>02142</u> <hr/> (City) (State) (Zip)	<b>2. Date of Event Requiring Statement (Month/Day/Year)</b> <u>06/30/2014</u>	<b>3. Issuer Name and Ticker or Trading Symbol</b> <u>Minerva Neurosciences, Inc. [ NERV ]</u> <hr/> <b>4. Relationship of Reporting Person(s) to Issuer (Check all applicable)</b> <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)	<b>5. If Amendment, Date of Original Filed (Month/Day/Year)</b> <u>06/30/2014</u> <hr/> <b>6. Individual or Joint/Group Filing (Check Applicable Line)</b> <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person
---	---	---	--

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Stock Option (right to buy)</u>	<u>(1)(2)</u>	<u>12/19/2023</u>	<u>Common Stock</u>	<u>80,356<sup>(2)</sup></u>	<u>9.49<sup>(2)</sup></u>	<u>D</u>	

**Explanation of Responses:**

1. Of the shares underlying this option, (a) 12.5% were vested and exercisable on the date of the original filing of this Form 3, (b) 25% vested and became exercisable on the closing date of the Company's initial public offering, and (c) the remaining shares will vest and become exercisable in 30 equal monthly installments upon Mr. Beer's completion of each month of service to the Company measured from June 20, 2013, such that the option will be fully vested on December 20, 2016.
2. This amendment is being filed to correct the following: (a) the number of shares underlying the option, (b) the exercise price of the option, and (c) the vesting schedule of the option.

**Remarks:**/s/ Marc D. Beer09/26/2014

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.